Getting recommended amounts of physical activity is linked to a lower risk for 7 cancer types, according to a study from the American Cancer Society, the National Cancer Institute, and the Harvard T.H. Chan School of Public Health.
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
The US Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab) to treat people with some types of skin lymphoma.
The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) to treat adults with certain types of large B-Cell lymphoma.